HRP20100147T1 - Inhibitori proteina akt (protein kinaza b) - Google Patents

Inhibitori proteina akt (protein kinaza b) Download PDF

Info

Publication number
HRP20100147T1
HRP20100147T1 HR20100147T HRP20100147T HRP20100147T1 HR P20100147 T1 HRP20100147 T1 HR P20100147T1 HR 20100147 T HR20100147 T HR 20100147T HR P20100147 T HRP20100147 T HR P20100147T HR P20100147 T1 HRP20100147 T1 HR P20100147T1
Authority
HR
Croatia
Prior art keywords
compound according
compound
treatment
glioblastoma
pharmaceutical preparation
Prior art date
Application number
HR20100147T
Other languages
English (en)
Croatian (hr)
Inventor
Joseph Sajan
Li Renhua
Ray Myers Michael
Aburub Aktham
Pingqi Dai Jenny
Randall Schmid Christopher
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20100147T1 publication Critical patent/HRP20100147T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
HR20100147T 2006-06-20 2010-03-15 Inhibitori proteina akt (protein kinaza b) HRP20100147T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80526006P 2006-06-20 2006-06-20
US88576507P 2007-01-19 2007-01-19
PCT/US2007/070945 WO2007149730A2 (en) 2006-06-20 2007-06-12 Inhibitors of akt (protein kinase b)

Publications (1)

Publication Number Publication Date
HRP20100147T1 true HRP20100147T1 (hr) 2010-04-30

Family

ID=38834248

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100147T HRP20100147T1 (hr) 2006-06-20 2010-03-15 Inhibitori proteina akt (protein kinaza b)

Country Status (28)

Country Link
US (1) US7998977B2 (da)
EP (1) EP2035385B1 (da)
JP (1) JP2009541335A (da)
KR (1) KR101067551B1 (da)
AR (1) AR061240A1 (da)
AT (1) ATE455102T1 (da)
AU (1) AU2007261120A1 (da)
BR (1) BRPI0713136A2 (da)
CA (1) CA2652612A1 (da)
CL (1) CL2007001752A1 (da)
DE (1) DE602007004333D1 (da)
DK (1) DK2035385T3 (da)
DO (1) DOP2008000053A (da)
EA (1) EA015712B1 (da)
EC (1) ECSP088992A (da)
ES (1) ES2336630T3 (da)
HR (1) HRP20100147T1 (da)
IL (1) IL195005A0 (da)
MA (1) MA30757B1 (da)
MX (1) MX2008015904A (da)
NO (1) NO20090289L (da)
PE (1) PE20080338A1 (da)
PL (1) PL2035385T3 (da)
PT (1) PT2035385E (da)
SI (1) SI2035385T1 (da)
TN (1) TNSN08529A1 (da)
TW (1) TW200812970A (da)
WO (1) WO2007149730A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217047B2 (en) 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
MX2014003856A (es) 2011-10-10 2015-01-16 Ampio Pharmaceuticals Inc Dispositivos medicos implantables con tolerancia inmune incrementada y metodos para hacerlos e implantarlos.
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
EP2771007B1 (en) 2011-10-28 2018-04-04 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
US9808454B2 (en) 2013-03-15 2017-11-07 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
KR20170045274A (ko) 2014-08-18 2017-04-26 앰피오 파마슈티컬스 인코퍼레이티드 관절 징후의 치료
WO2016201605A1 (zh) * 2015-06-15 2016-12-22 廖勇 一种治疗乙型肝炎病毒的靶点
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CA3186562A1 (en) * 2020-07-22 2022-01-27 Jian Wu Salt and crystal form of dihydropyrido[2,3-d]pyrimidine derivate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152807A0 (en) 2000-05-30 2003-06-24 Peptor Ltd Protein kinase inhibitors
US7414063B2 (en) * 2003-03-28 2008-08-19 Eli Lilly And Company Inhibitors of Akt (protein kinase B)
GB0317315D0 (en) 2003-07-24 2003-08-27 Astex Technology Ltd Pharmaceutical compounds
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)

Also Published As

Publication number Publication date
PT2035385E (pt) 2010-03-01
SI2035385T1 (sl) 2010-05-31
JP2009541335A (ja) 2009-11-26
EP2035385A2 (en) 2009-03-18
US7998977B2 (en) 2011-08-16
BRPI0713136A2 (pt) 2012-04-17
CL2007001752A1 (es) 2008-01-18
MX2008015904A (es) 2009-01-12
TNSN08529A1 (en) 2010-04-14
DE602007004333D1 (de) 2010-03-04
AR061240A1 (es) 2008-08-13
IL195005A0 (en) 2009-08-03
WO2007149730A2 (en) 2007-12-27
AU2007261120A1 (en) 2007-12-27
NO20090289L (no) 2009-01-19
CA2652612A1 (en) 2007-12-27
PL2035385T3 (pl) 2010-06-30
TW200812970A (en) 2008-03-16
WO2007149730A3 (en) 2008-04-24
ATE455102T1 (de) 2010-01-15
ES2336630T3 (es) 2010-04-14
MA30757B1 (fr) 2009-10-01
DOP2008000053A (es) 2009-01-15
EA015712B1 (ru) 2011-10-31
EP2035385B1 (en) 2010-01-13
DK2035385T3 (da) 2010-03-22
PE20080338A1 (es) 2008-04-25
EA200970041A1 (ru) 2009-06-30
KR101067551B1 (ko) 2011-09-27
KR20090015978A (ko) 2009-02-12
ECSP088992A (es) 2009-01-30
US20090221633A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
HRP20100147T1 (hr) Inhibitori proteina akt (protein kinaza b)
EA038122B9 (ru) Ингибитор поверхностного антигена вируса гепатита b
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
TN2018000219A1 (en) Soluble guanylate cyclase stimulators
HRP20171197T1 (hr) Bifenilsulfonamidni antagonist receptora endotelina i angiotensina ii, namijenjen liječenju glomeruloskleroze
WO2007042786A3 (en) 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors
RS50600B (sr) Kristalni oblik gama - d ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
SG11201901894TA (en) Anti-influenza virus pyrimidine derivatives
MX2015017345A (es) Compuestos para tratar atrofia muscular espinal.
HRP20201681T1 (hr) Inhibitor aurora a kinaze
MX371167B (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
TW200630347A (en) Quinazoline derivatives
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
MX2015016513A (es) Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo.
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
MY167216A (en) Kinase inhibitors
EA201792072A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения